熱門資訊> 正文

Sandoz暂时批准辉瑞Inlyta仿制药

2025-10-10 23:07

輝瑞(PFE) 0
團車網(TC) 0
SANDOZ GROUP AG SPON ADS EACH REP 1 COM SHS(SDZNY) 0

The U.S. FDA has given tentative approval to Sandoz (OTCQX:SDZNY) for a generic version of Pfizer's (NYSE:PFE) kidney cancer drug Inlyta (axitinib).
The tentative approvals are for both the 1 mg and 5 mg tablets.
The axitinib generic cannot be launched immediately due to patent litigation filed in November 2024 by Pfizer against Sandoz (OTCQX:SDZXF) alleging that a key Inlyta patent is infringed. That patent expires in June 2031.
In Q2, Inlyta had global sales of $243M.

More on Pfizer

Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy
Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers
Dividend Roundup: Lockheed Martin, Pfizer, Genpact, Delta Air Lines, and more
Next CDC AdCom meeting on vaccines delayed

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。